Tareq Abadl: Persistent Anti-β2GPI IgG Is Not a Coincidence – It’s Pathology
Tareq Abadl, Medical Laboratory Specialist and Director of the Blood Bank at Dr. Abdelkader Al-Mutawakkil Hospital, shared a post on LinkedIn:
“β2 Glycoprotein I Antibodies — Made Simple
Many people hear the name β2 Glycoprotein I antibodies and get confused. Let’s break it down clearly
What is β2 Glycoprotein I?
β2 Glycoprotein I (β2GPI) is a normal plasma protein that binds to phospholipids and plays a role in regulating coagulation.
What does the test measure?
It detects autoantibodies against β2GPI, which are a core laboratory criterion for diagnosing Antiphospholipid Syndrome (APS).
IgG vs IgM — What’s the difference?
β2GPI – IgM
- Often rises in early or transient immune responses
- May be associated with infections, inflammation, or immune stress
- Can be temporary and disappear on repeat testing
- Lower diagnostic weight for APS
β2GPI – IgG
- Clinically more significant
- Persistent elevation strongly supports APS diagnosis
- More clearly associated with:
- Thrombosis
- Recurrent pregnancy loss
- Placental insufficiency
Bottom line: IgG is more reliable and more dangerous than IgM in terms of complications.
Important Laboratory Points
The test must be repeated after ≥12 weeks to confirm persistence
- Never interpret it alone
- APS diagnosis requires a panel, including:
- Lupus Anticoagulant (LA)
- Anticardiolipin antibodies (aCL)
- Anti-β2 Glycoprotein I antibodies
- Medium to high titers are required — low positives may be clinically irrelevant
Advanced lab note (important):
- IgG antibodies targeting Domain I of β2GPI are the most pathogenic and most strongly linked to thrombosis
- Solid-phase assays (ELISA/CLIA) must follow international APS cut-offs, not manufacturer-only ranges
Simple analogy Anti-β2GPI antibodies are like someone sabotaging traffic control
Blood flow loses balance to congestion to clots
If IgG is present and persistent, this is not coincidence — it’s pathology.”

Find more posts featuring Tareq Abadl on Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support